Capital One Initiates Coverage On Immunocore Hldgs with Overweight Rating, Announces Price Target of $84
Portfolio Pulse from richadhand@benzinga.com
Capital One analyst Naureen Quibria has initiated coverage on Immunocore Hldgs (NASDAQ:IMCR) with an Overweight rating and a price target of $84.
August 16, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunocore Hldgs has been given an Overweight rating by Capital One, with a price target of $84.
The Overweight rating from Capital One indicates a positive outlook for Immunocore Hldgs. The price target of $84 suggests a significant upside potential from the current price. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100